UNSPSC 51182029: Furazabol

This classification denotes an anabolic steroid with the molecular formula C20H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2W07HSP5PX, chemically known as 17-methyl-5alpha-androstano(2,3-c)furazan-17beta-ol but generally known as furazabol, which bears US NIH Compound Identifier 14708. European Medicines Agency schedules Furazabol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07833MIG. The term FURAZABOL is an International Non-Proprietary Name.

UNSPSC 51182029 Furazabol is a Commodity code that encompasses pharmaceutical products supplied through state and local cooperative purchasing agreements, specifically anabolic steroids and controlled pharmaceutical compounds. State and local governments source these products primarily through multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions and their healthcare facilities. The issuing bodies are predominantly state purchasing offices administering cooperative vehicles that bundle multiple states and localities; the Minnesota Department of Administration's Office of State Procurement, for example, operates the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which coordinates procurement across Minnesota, Oregon, and other participating member states and local government entities. Vendors supplying under this code must maintain FDA compliance, current Good Manufacturing Practices (cGMP) certification, and Drug Supply Chain Security Act (DSCSA) compliance, establish relationships with authorized pharmaceutical wholesalers (AmerisourceBergen/Cencara, Cardinal Health, Morris & Dickson), and carry substantial insurance including $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability per occurrence.

The code shows recent activity centered on the upper Midwest, with MMCAP's current RFP issued January 20, 2026 (due March 26, 2026) representing the most visible recent opportunity. MMCAP's generic multi-source pharmaceuticals and OTC products RFP establishes multiple contracts effective July 1, 2026, with a two-year initial term and optional extensions; price competitiveness carries 75 percent evaluation weight, while fixed pricing, format compliance, EDI capability, and administrative-fee acceptance each account for 5 to 10 percent. Vendors must supply products through three authorized wholesalers with chargeback systems in place, offer flexible pricing structures (flat price, net price formats at 30/60/90 days, or WAC-minus), and comply with performance penalties of $200 to $1,500 per violation. No specific award value or budget is disclosed. Submissions use the ePro procurement system in CSV format with supporting documentation emailed to MMCAP_Infuse.RFP@state.mn.us; the question cutoff was February 18, 2026.